---
schema_version: "secwatch.filing_event.v1"
accession: "0001034842-26-000038"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2026-05-12T21:24:38+00:00"
generated_at: "2026-05-12T21:26:47.825316+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones

## Summary
- Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
- Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.
- Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.
- VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
- Deal subject to HSR waiting period expiration or termination.

## SEC filing metadata
- accession: 0001034842-26-000038
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2026-05-12T21:24:38+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/0001034842-26-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/rigl-20260511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001034842-26-000038
- JSON: https://secwatch.observer/filing/0001034842-26-000038.json
- Plain text: https://secwatch.observer/filing/0001034842-26-000038.txt

## Key facts
- Material Agreements
  RIGEL PHARMACEUTICALS INC entered into Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. valued at $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest (effective 2026-05-11).
  - Action: entry
  - Agreement: license
  - Counterparty: Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc.
  - Value: $70 million upfront payment, $15 million transition completion payment, up to $320 million in milest
  - Effective: 2026-05-11
  source text: On May 11, 2026, Rigel Pharmaceuticals, Inc. ("Rigel" or the "Company") entered into a License Agreement (the "Agreement") with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer Inc. (collectively, the "Licensors").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/0001034842-26-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.